The 2025 APAC Health and Life Sciences Summit – Spotlight Indonesia successfully took place on 3 June in Jakarta. Co-hosted by the Ministry of Health of Republic of Indonesia and ASK Health Asia, this year’s summit marked the first country-focused edition of the APAC Health and Life Sciences Partnership Platform. It brought together over 150 speakers and participants from more than 10 countries across the region, including senior policymakers, industry leaders, international organisations, academic institutions, and investors, creating a high-level platform for cross-sectoral dialogue and partnership in Indonesia.

The day opened with welcome remarks from the hosts, Dr. Chang Liu, Founder and CEO of ASK Health Asia, and Andreas Donny Prakasa, Head of Corporate Relationship at PT Etana Biotechnologies Indonesia.

The summit featured a series of deep-dive sessions designed to explore the intersection of policy, collaboration and investment in strengthening Indonesia’s health and life sciences ecosystem.

Subsequent opening speeches were delivered by senior leaders from the Indonesian Ministry of Health and other key government agencies.

Budi Gunadi Sadikin, Minister of Health of the Republic of Indonesia, opened the summit by delivering remarks underscoring the government’s commitment to transforming the national health system and fostering international partnerships to promote equity, access, and innovation across the region. He highlighted the urgent need for health policy reform in Indonesia and emphasized the importance of adopting new technologies and innovative service models to deliver higher-quality, more affordable care. Minister Budi also invited international companies to invest in Indonesia’s rapidly growing healthcare sector, noting that national health spending is expected to increase over the next five years. He highlighted that Indonesia’s large population and healthcare infrastructure present a unique and promising opportunity for global stakeholders.

Dr. Laksana Tri Handoko, Chairman of the National Research and Innovation Agency (BRIN), emphasized the importance of research-driven collaboration to advance sustainable health and life sciences development in Indonesia. He introduced BRIN’s open-access business model, which “opens all researchers and facilities to be accessed by any local and global partners—academic or industry—based on a co-development scheme, sharing both publications and intellectual properties.” Dr. Handoko highlighted BRIN’s focus on utilizing local renewable natural resources to tackle local health challenges, such as developing halal vaccines using microalgae, affordable diagnostics, and portable medical equipment. “We aim to enable private-sector-driven innovation by leveraging our national biodiversity and infrastructure,” he noted, referencing BRIN’s management of over 2 million biological specimens across Indonesia.

Dr. Taruna Ikrar, Head of the Indonesian Food and Drug Agency (BPOM), outlined Indonesia’s ongoing regulatory reforms and emphasized the importance of strategic coordination to advance public health, strengthen regulatory systems, and foster innovation in the life sciences sector. He noted that “our institution has been working intensively to align with global best practices,” and stressed that “this is more than just regulatory reform—it is a commitment to public health, quality of life, and global recognition.” Dr. Ikrar highlighted BPOM’s growing collaboration with international agencies and underscored the critical need to invest in human resources, infrastructure, and more effective regulatory mechanisms. Concluding his remarks, he affirmed, “With the right partners, policies, and platforms, we can turn vision into reality and build a responsive, resilient, and innovation-driven health system for Indonesia and beyond.”

The first session focused on Indonesia’s ongoing reforms and their implications for health policies and life sciences industry development.

The keynote address was delivered by Dr. L. Rizka Andalucia, Director General for Pharmaceutical and Medical Devices at the Ministry of Health, who provided a comprehensive overview of Indonesia’s pharmaceutical and medical device landscape, as well as ongoing health system transformation and regulatory developments. She emphasized that the government of Indonesia is firmly committed to health system transformation, which is being advanced through six strategic pillars aimed at improving access, quality, and resilience across all levels of care. Dr. Rizka highlighted that the Ministry of Health has developed an inclusive and integrated strategy to foster an ecosystem that enables research, innovation, and multi-stakeholder collaboration. In support of these goals, the government has enacted key legislative and regulatory frameworks—including the Health Omnibus Law and related regulations—to build a stronger, more equitable, and innovation-friendly healthcare system. As Dr. Rizka concluded, “We are proud to contribute by inviting strategic co-investment in areas where innovation meets impact and partnership drives sustainable progress.”

A second keynote was presented by Dr. Tri Asti Isnariani, Acting Deputy for Supervision of Medicines, Narcotics, Psychotropics, Precursors, and Addictive Substances at the Indonesian Food and Drug Agency (BPOM), delivered a presentation focused on regulatory reform and regional collaboration to build a Medicine and Vaccine Development Ecosystem. She outlined Indonesia’s commitment to strengthening the full product life cycle—from R&D to post-market surveillance—by implementing Good Regulatory Practices, digitizing processes, and aligning with international standards. “We are building a regulatory ecosystem that supports both innovation and safety,” Dr. Isnariani stated, emphasizing BPOM’s role in facilitating clinical trials, accelerating approvals, and supporting local manufacturing through reliance models and technical assistance. She also highlighted successful models of collaboration in Indonesia, such as Indonesian FDA Role in building access to local Covid-19 vaccine production. In closing, she stressed, “Collaboration is key to achieving better access, stronger innovation, and more equitable health outcomes.”

Following the keynotes, a high-level roundtable discussion was held, moderated by Eugene Hong, Head of Healthcare and Pharmaceutical, Institutional Banking Group at DBS Bank. The session brought together diverse perspectives from across the region, including Daniel Katz, General Manager for South East Asia at Bristol Myers Squibb Pharma (Thailand) Ltd.; Professor John CW Lim, Executive Director of the Centre of Regulatory Excellence at Duke-NUS Medical School and Senior Advisor to the Ministry of Health, Singapore; Professor David Barry Hipgrave, Lead for Research at the SingHealth Duke-NUS Global Health Institute; Ye Xu, Senior Health Specialist at the Asian Development Bank; Neeraj Jain, Director of Growth Operations for Asia, the Middle East and Europe at PATH; and Audrey Clarissa, Vice Chair of Business Development at GP Farmasi Indonesia (GPFI). During the roundtable, panelists discussed Indonesia’s sweeping healthcare policy reforms, emphasizing their potential to drive greater access, quality, and innovation across the system. Experts from development agencies and academia highlighted the key policy drivers, and industry leaders shared perspectives on how these reforms are unlocking innovation and market opportunities. Several speakers pointed to digital health, local manufacturing, and cross-sector collaboration as promising growth areas. This roundtable concluded with a shared optimism about Indonesia’s potential to lead ASEAN in healthcare innovation and equitable service delivery.

The next session turned to the theme of cross-regional collaboration, moderated by Charlene Huang, Partner at Global Law Office. The panel brought together Paul Huleatt, Counsellor (Health) at the Australian High Commission in Singapore and Regional Advisor for the Indo-Pacific Regulatory Strengthening Program at the Australian Therapeutic Goods Administration (TGA); Wenfeng Gong, Deputy Director for Health, Innovation & Partnership at the Bill & Melinda Gates Foundation; Zhiliang Tu, Founder and Chairman of Gushengtang Traditional Chinese Medicine Chain Management Group; Yuan Lu Ho, Vice President of Partnership, Strategic Planning and Outreach at the Diagnostics Development Hub; Yaping Shen, Vice President at Jiangsu Hengrui Pharmaceuticals; Amira Ghouaibi, Head of the Global Alliance for Women’s Health at the World Economic Forum; and Chaonan Qian, President of Guangzhou Concord Cancer Center. They explored the role of partnerships in addressing access gaps and aligning innovation efforts across countries. Panelists highlighted successful partnership models between public, private, and philanthropic sectors in addressing systemic health challenges. The discussion also emphasized the critical role of such collaborations in overcoming barriers to health equity, particularly in emerging economies like Indonesia.

The first session in the afternoon focused on building capacity for life science innovation in Indonesia.

Ms. Dita Novianti, Director of Pharmaceutical Production and Distribution, Ministry of Health, Republic of Indonesia, delivered afternoon opening remarks on building capacity for life science innovation in Indonesia, emphasizing that the primary goal of health innovation is to improve public health outcomes and ensure effective implementation across the healthcare system. She highlighted the Ministry’s ongoing efforts to enhance access to quality health products and technologies, aligned with Indonesia’s broader healthcare transformation vision. Ms. Novianti called for continued multi-sector collaboration, evidence-based policymaking, and regional partnerships to build a more resilient, inclusive, and innovation-oriented healthcare system. She expressed hope that through collective dialogue and action, Indonesia can lead regional progress in health innovation and improve outcomes for all.

Professor Auliya A. Suwantika, Chair of InaHTAC, Ministry of Health, Republic of Indonesia, delivered a keynote address on the newly established Health Technology Assessment (HTA) business process designed to accelerate life science innovation in Indonesia. He began by outlining Indonesia’s broader healthcare transformation agenda, grounded in the vision of fostering a healthy, productive, independent, and equitable society. Professor Suwantika highlighted the significant milestones achieved in institutionalizing HTA, which has become a critical tool for the Ministry of Health in guiding decisions on new technology adoption. He presented the newly developed HTA business process in detail and called for multi-stakeholder collaboration to support sustainable health system transformation.

Nathan Tirtana, President Director of Etana Biotechnologies Indonesia, delivered a keynote on shaping the future of life sciences in Indonesia. He introduced Etana’s three strategic pillars for building local capabilities: Quality & Access, Knowledge Transfer, and Collaboration. Mr. Tirtana also highlighted the national burden of diseases such as Tuberculosis (TB), Diabetes, Chronic Kidney Disease, and Cancer, using them as examples to illustrate both the healthcare challenges Indonesia faces and the innovative solutions being developed. He concluded by outlining Etana’s vision for contributing to the advancement of Indonesian healthcare through localized innovation and strategic partnerships.

A roundtable moderated by Giles Newmarch, Senior Investment Officer at the International Finance Corporation (IFC), explored investment and operational strategies shaping the future of health and life sciences in Asia. The session brought together Jusong Xia, President of International Business at United Imaging Healthcare; Xingrong Chen, CEO of Fosun Kairos; Frank Wu, General Manager of International Business at 3SBIO Inc.; Navjeewan Khosla, Partner at Novo Holdings; Dr. Suci Melati Wulandari, Assistant Professor at the Centre for Outbreak Preparedness, Duke-NUS Medical School and affiliated with the SingHealth Duke-NUS Global Health Institute; and Dr. Anwar Santoso, member of the Supervisory Board at IASMED. Panelists explored Indonesia’s capacity-building efforts to support life science innovation, with a focus on clinical research, talent development, and regulatory strengthening. Discussions also highlighted the need for robust HTA systems, enhanced domestic manufacturing capabilities, and streamlined regulatory processes. Panelists shared insights on public-private partnerships, the evolving needs of the Indonesian market, and how regional cooperation—particularly with China and other global stakeholders—can accelerate progress and position Indonesia as a leader in Southeast Asia’s life sciences landscape. The session concluded with a shared vision of Indonesia emerging as a key innovation hub in the region—provided that strategic investment and cross-sector collaboration continue to advance.

A highlight of the summit was the Innovator Showcase segment, which featured pioneering work from across Asia’s life sciences ecosystem.

Jun Yan of Gushengtang presented the company’s strategic approach to Traditional Chinese Medicine (TCM), outlining its business models across different markets and sharing insights into future expansion plans.

Kate Qi of SG Diagnostics introduced innovative solutions in health management systems, emphasizing point-of-care diagnostics, health education, and data collection capabilities. She also shared SG Diagnostics’ operational experience in Hong Kong and Singapore, with the aim of contributing to population-wide health improvement in Indonesia.

Jason Gao of iKang showcased the company’s integrated service platform and nationwide network, highlighting its unique value proposition driven by digital transformation, including the use of AI and big data.

Abby Tan Chee Hong of EVYD Technology shared the company’s vision to “build a future where everyone can access better health.” He provided a detailed overview of EVYD’s capacities in digital transformation and data governance, and their broader contributions to advancing the healthcare ecosystem.

The topic of sustainable health financing was the focus of the next session.

Chang Liu moderated a forward-looking panel that explored the evolving landscape of health financing and insurance innovation across the region. The discussion brought together Yosie William Iroth, Chief Health Officer at Prudential Indonesia; Iwan Pasila, Deputy Commissioner of Insurance, Guarantee Institutions, and Pension Fund Supervision at the Financial Services Authority of Indonesia (OJK); Yao Lei, Associate Director (Research and Dialogue) and Health Lead at the Global Asia Insurance Partnership (GAIP); Paul Setio Kartono, President of the Society of Actuaries Indonesia (PAI); and Edward Booty, CEO of reach52.

This roundtable examined Indonesia’s journey toward universal health coverage, focusing on the achievements and sustainability challenges of the national health insurance program (JKN). Participants explored how private insurance and coordinated financing models could complement JKN to expand access to innovative therapies. Discussions also highlighted experience from sustainable Asian healthcare financing systems, e.g., Singapore, analyzing models that balance affordability, innovation, and equity to inform Indonesia’s next-phase reforms.

Ahmad Irsan A. Moeis, Director for Health Financing at the Ministry of Health, presented an in-depth introduction to Indonesia’s healthcare expenditure, analysing the specifics of each financing scheme. He also highlighted Indonesia’s journey with its national insurance scheme (JKN), along with strategies to expand coverage and improve long-term sustainability.

The final session examined the investment landscape for life sciences in Indonesia. Moderated by Barney Yao, Managing Director at Haitong International, the roundtable convened key voices from across the investment and biotech ecosystem, including May Lo, Investment Director at abc Impact, Temasek Trust Asset Management; Jiadi Yu, Chief Investment Officer at the International Finance Corporation (IFC); Sean Shi, Director and CEO of Sino-Innovax Biotec Pte Ltd; Alva Chen, Managing Director for Healthcare at VMS Group; and Vijay Karwal, Managing Director at CBC Group. They shared practical insights on how local companies can navigate the funding environment, scale impact, and attract long-term strategic capital. The discussion also touched on regulatory predictability, valuation alignment, and cross-border opportunities. This roundtable examined investment opportunities in Indonesia’s rapidly growing life sciences sector, driven by market expansion, infrastructure development, and health system reforms. Participants analysed high-potential areas like diagnostics and pharmaceuticals. Discussions spotlighted the key successful factors of partnership between foreign investors, local companies, and government agencies that can jointly accelerate R&D and innovation.

Closing the summit, co-hosts Andreas Donny Prakasa and Dr. Chang Liu extended heartfelt thanks to all partners and speakers for their contributions to a meaningful day of learning, exchange, and connection.

Dr. Liu noted that Indonesia’s leadership and openness to collaboration not only made the summit impactful, but also reaffirmed ASK Health Asia’s commitment to advancing country-level innovation and fostering regional partnerships.

As part of the Summit programme, a business visit to Jakarta was organized, where industry leaders from across Asia engaged in candid and constructive discussions with key Indonesian stakeholders, including the Ministry of Health and the International Finance Corporation (IFC). A major highlight of the visit was a Closed-Door Meeting personally chaired by Indonesia’s Minister of Health, Mr. Budi Gunadi Sadikin, focusing on cross-regional collaboration and future initiatives in Indonesia.

This summit would not have been possible without the strong support of our strategic partners: SingHealth Duke-NUS Global Health Institute, Haitong International, Etana, and the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), as well as our Knowledge Partner, the Centre of Regulatory Excellence (CoRE) at Duke-NUS Medical School.

Together, we look forward to building on this momentum to co-create innovative, sustainable, and inclusive solutions for health systems across Asia.

Vibrant Jakarta! Dynamic Indonesia! ?Shaping health futures in Asia!

The post Unlocking Innovation and Investment for the Next Generation of Health and Life Sciences in Indonesia – Connecting Leaders and Innovators at the 2025 APAC Health and Life Sciences Summit appeared first on 艾社康（上海）健康咨詢有限公司.

4月25日，“加強(qiáng)醫(yī)保和商保的有效銜接，支持創(chuàng)新藥械發(fā)展”會(huì)議在上海圓滿舉辦。本場(chǎng)會(huì)議由中國(guó)醫(yī)藥教育協(xié)會(huì)、北京中康聯(lián)公益基金會(huì)、北京中健聯(lián)健康服務(wù)促進(jìn)中心聯(lián)合主辦，艾社康承辦。

本屆會(huì)議特邀多位中央和地方醫(yī)保局領(lǐng)導(dǎo)、多層次醫(yī)療保障相關(guān)政策專家、保險(xiǎn)行業(yè)代表，以及藥械產(chǎn)業(yè)代表為核心嘉賓，分享完善多層次醫(yī)療保障制度體系的思路與先進(jìn)經(jīng)驗(yàn)，探索基本醫(yī)保與商業(yè)健康險(xiǎn)更緊密地協(xié)同與銜接，共同支持創(chuàng)新藥械發(fā)展。

本次會(huì)議得到了諾華、輝瑞、阿斯利康、銀諾醫(yī)藥、益普生、RDPAC的大力支持；并獲得E藥經(jīng)理人、鳳凰網(wǎng)財(cái)經(jīng)、醫(yī)衛(wèi)界、慢病界、微解藥以及眾多業(yè)內(nèi)主流媒體的宣傳報(bào)道。

The post “加強(qiáng)醫(yī)保和商保的有效銜接，支持創(chuàng)新藥械發(fā)展”會(huì)議成功舉辦 appeared first on 艾社康（上海）健康咨詢有限公司.

4月22日上午，由上海氣候周執(zhí)行委員會(huì)、艾社康（ASK Health Asia）與上海紐約大學(xué)城市設(shè)計(jì)與城市科學(xué)重點(diǎn)實(shí)驗(yàn)室（LOUD）聯(lián)合舉辦的“可持續(xù)城市未來(lái)：氣候韌性、脫碳行動(dòng)與健康生態(tài)的協(xié)同路徑”主題論壇在上海環(huán)境能源交易所圓滿落幕。來(lái)自全球的科學(xué)家、企業(yè)家、慈善機(jī)構(gòu)代表及政策制定者齊聚一堂，圍繞氣候變化與健康協(xié)同適應(yīng)、綠色醫(yī)療轉(zhuǎn)型等議題展開深度對(duì)話，共同探索氣候韌性未來(lái)的創(chuàng)新路徑。

The post “可持續(xù)城市未來(lái)：氣候韌性、脫碳行動(dòng)與健康生態(tài)的協(xié)同路徑”主題論壇圓滿落幕 appeared first on 艾社康（上海）健康咨詢有限公司.

1月29日，在于泰國(guó)曼谷舉辦的PMAC 2025大會(huì)期間，艾社康作為合作伙伴參與了由公益慈善研究院（Institute of Philanthropy）和聯(lián)合國(guó)開發(fā)計(jì)劃署（United Nations Development Programme-UNDP）舉辦的數(shù)字健康專題研討會(huì): Catalysing Digital Technologies for Non-communicable Diseases in the Global South。

在本次PMAC大會(huì)期間的專題研討會(huì)中，艾社康正式發(fā)布了題為Philanthropy as a Catalyst of Digital Technology for Better Healthcare: From China to the World的研究報(bào)告。報(bào)告對(duì)數(shù)字技術(shù)在中國(guó)醫(yī)療健康行業(yè)的應(yīng)用情況、中國(guó)數(shù)字醫(yī)療政策進(jìn)行了全面梳理。通過(guò)對(duì)四個(gè)最具影響力和代表性的項(xiàng)目的分析，總結(jié)出技術(shù)應(yīng)用的主要挑戰(zhàn)。同時(shí)，報(bào)告展現(xiàn)了當(dāng)前慈善機(jī)構(gòu)和其他跨領(lǐng)域相關(guān)方促進(jìn)數(shù)字技術(shù)在醫(yī)療健康應(yīng)用的嘗試、存在的價(jià)值，并提供了一系列實(shí)操建議。

The post 艾社康于曼谷參與數(shù)字健康主題研討會(huì) appeared first on 艾社康（上海）健康咨詢有限公司.

2024年11月28-29日，第二屆灣區(qū)醫(yī)療衛(wèi)生事業(yè)協(xié)同發(fā)展大會(huì)在廣州成功召開。本屆大會(huì)由中國(guó)醫(yī)藥保健品進(jìn)出口商會(huì)、廣東省衛(wèi)生經(jīng)濟(jì)學(xué)會(huì)、北京全齡社區(qū)健康促進(jìn)中心、北京中健聯(lián)健康服務(wù)促進(jìn)中心聯(lián)合主辦，中新廣州知識(shí)城、深圳市生命科學(xué)與生物技術(shù)協(xié)會(huì)支持，艾社康承辦。

大會(huì)得到了諸多領(lǐng)導(dǎo)和專家的指導(dǎo)和支持，邀請(qǐng)到了商務(wù)部駐廣州特派員王東、國(guó)家及粵港澳大灣區(qū)衛(wèi)健、藥監(jiān)、醫(yī)療保障系統(tǒng)相關(guān)領(lǐng)導(dǎo)，行業(yè)協(xié)會(huì)代表，政策研究專家，國(guó)內(nèi)外生物醫(yī)藥及醫(yī)療器械代表、保險(xiǎn)行業(yè)代表等出席分享。大會(huì)也得到了輝瑞、默沙東、上藥控股、艾伯維、益普生、信達(dá)、再鼎醫(yī)藥、華潤(rùn)廣東醫(yī)藥等眾多投身大灣區(qū)醫(yī)藥創(chuàng)新發(fā)展的企業(yè)伙伴的支持。

本次大會(huì)支持媒體有南方日?qǐng)?bào)、南方都市報(bào)、廣州日?qǐng)?bào)、澳門日?qǐng)?bào)；戰(zhàn)略合作媒體為八點(diǎn)健聞、E藥經(jīng)理人、醫(yī)學(xué)界、新浪財(cái)經(jīng)；合作媒體包括鳳凰網(wǎng)財(cái)經(jīng)、醫(yī)衛(wèi)界、慢病界、微解藥、張通社、張江頭條。

本次大會(huì)的召開，讓我們更加有信心看到大灣區(qū)的醫(yī)療衛(wèi)生事業(yè)會(huì)以更開放的姿態(tài)、更創(chuàng)新的路徑，走出一條符合自身特色、符合國(guó)家戰(zhàn)略、對(duì)全球醫(yī)療健康產(chǎn)業(yè)發(fā)展具有示范意義的道路。相信在各方的攜手推動(dòng)下，大灣區(qū)的醫(yī)療衛(wèi)生事業(yè)必將煥發(fā)出更加蓬勃的生機(jī)，為實(shí)現(xiàn)“健康中國(guó)”與醫(yī)療衛(wèi)生體制改革目標(biāo)書寫更加輝煌的篇章，為全球健康事業(yè)的可持續(xù)發(fā)展注入強(qiáng)大動(dòng)力，為全世界貢獻(xiàn)更多可持續(xù)的“中國(guó)方案”，進(jìn)一步彰顯大灣區(qū)乃至全中國(guó)在全球健康治理中的智慧與擔(dān)當(dāng)。

The post 第二屆灣區(qū)醫(yī)療衛(wèi)生事業(yè)協(xié)同發(fā)展大會(huì)圓滿落幕 appeared first on 艾社康（上海）健康咨詢有限公司.

Carrie Liu of the World Economic Forum, Dr Chang Liu, founder and CEO of ASK Health Asia, and Associate Professor Jonas Karlstrom, Innovation Core Lead at SingHealth Duke-NUS Global Health Institute moderated the event. In the opening remarks, the hosts shared how this year’s summit marked the establishment of the APAC Health and Life Science Partnership Platform, a collaborative initiative uniting public and private stakeholders to drive transformative solutions and foster equitable access to high-quality care across the Asia and Pacific region. The Singapore Economic Development Board (EDB) highlighted the importance of innovation in healthcare and life sciences for Asia’s rapidly evolving landscape and reaffirmed Singapore’s strategic role in facilitating collaboration and creating value across the region.

Partnering and Innovating for Equity and Access Across APAC

The first morning of the summit focused on two key topics, “The APAC Growth Story” and “The APAC Life Science Innovation Landscape,” offering valuable insights into the region’s dynamic development and innovation potential.

A Country Highlights session featured insights from Australia, India and China. Dr Paul Huleatt, Counsellor (Health) at the Australian High Commission, Singapore, and Regional Advisor for the Indo-Pacific Regulatory Strengthening Program, underscored that strengthening regulatory frameworks in the Asia Pacific region depends on collaborative partnerships, evidence-based decision making and the continuous improvement of regulatory practices. Siddhartha Bhattacharya, Secretary General of NATHEALTH, highlighted key opportunities in India’s healthcare, focusing on innovation, digital health, infrastructure and global integration through public-private partnerships. ? Lin Shi, Policy Director of PhRMA China Office, stated, “China’s biopharmaceutical R&D pipeline has grown by 784% over the past decade, becoming the second largest globally after the United States. This growth was driven by supportive policies such as regulatory reforms. An innovative biopharmaceutical ecosystem is key to continue to enhance innovation and improve patient access.”

Dr Snehal Patel, Co-founder of aEQ and Managing Director of Saena Partners, and Carrie Liu, Lead for Health and Healthcare at the World Economic Forum, moderated panels that explored cross-regional health innovation and the development of a supportive ecosystem for life sciences in APAC. Speakers from the Health and Global Policy Institute (HGPI) Japan, Australian High Commission Singapore, ProtectHealth Corporation and Ministry of Health Malaysia, the American Chamber of Commerce in Singapore, Bristol Myers Squibb, Eli Lilly and Apollo Hospitals shared their perspectives on cross-regional cooperation to advance health equity and access. The panel underscored the importance of innovation and regulatory harmonization in addressing challenges and improving health outcomes for all. They discussed specific models of stakeholder collaboration that have had measurable impact on access and how to take those lessons and apply them to other areas of need.

Panel Discussions: Cross-regional Commitment to Health Innovation for Equity and Access

Speakers from A*Star, the Experimental Drug Development Centre (EDDC), JLABS Singapore, CBC Group, and PATH South Asia shared insights on fostering innovation in the APAC life sciences sector. The panel explored strategies to advance R&D, overcome regulatory fragmentation, and promote sustainable investments, emphasizing the importance of building a collaborative ecosystem. Dr Alessandro Falcone, Regional Head of JLABS Singapore, outlined the three key pillars necessary for life science innovation: science, expertise, and funding. “In the current volatile landscape, companies that pivot and adapt quickly are the ones that thrive. This includes reassessing product focus, geographic strategy, and even leadership structure,” he emphasized.

In the “Innovator Showcase” session, leaders from BeiGene, Pilatus Biosciences, Hugo Biotech presented examples of cutting-edge Asian life sciences innovation for the region as well as the global market.? For instance, the digital transformation of pathology, highlighting automating complex procedures and centralizing sequencing analysis, has led to a substantial reduction of costs and accuracy of microbiology testing.

The afternoon session began with the topic of “Creating a Vibrant Life Sciences Market in APAC”, in partnership with DBS Bank, GenScript and Sino-Innovax. The showcase session featured leading organisations of the life science innovation value chain, including GenScript, ATLATL Scientific, SG Diagnostics, and George Clinical. Dr Janice Jin, President of GenScript Asia Pacific, highlighted the company’s four-pronged approach: “We’ve made meaningful impacts in supporting local research, engaging with the community, nurturing local talent, and fulfilling corporate social responsibilities.”

The panels, “Partnering for Success: A Dialogue” and “Innovative Financing for Improved Access,” explored strategies to advance APAC’s life sciences market through cross sectoral and cross regional collaboration and sustainable innovative financing. Moderated by Giles Newmarch, Senior Investment Officer, lFC-International Finance Corporation (World Bank) and Dale Huntington, Senior Director, Health Care Systems Policy, Johnson and Johnson, the panels featured leaders from DBS Bank, Sino-Innovax Biotec, Diagnostics Development Hub, SCG Cell Therapy, Microsoft, Access Partnership, Pfizer, MSD Pharma, MSD for Mothers, aEQ, Heals Healthcare and MiyaHealth. Discussions focused on leveraging partnerships, technology to develop and bring more innovations to the market, as well as through tailored financing models to address improve access, bridge funding gaps, and drive innovation. Dr Eugene Hong, Head, Healthcare & Pharmaceutical at the Institutional Banking Group, DBS Bank, underscored the importance of a compelling narrative to attract investment. “Investors are drawn to projects that address pressing societal challenges. By framing key issues as urgent and solvable, we can mobilize capital more effectively”.

The next session, “the Asia Life Sciences Investor Forum”, was held in partnership with Haitong International. The panels, “Global Investment Supporting Asia Life Sciences Industry” and “Asian Investment Facilitating Regional Life Sciences Industry Cooperation,” highlighted the pivotal role of investment in advancing Asia’s life sciences ecosystem. Moderated by Stephen Ng, Managing Director and CEO of CICC Singapore, and Barney YAO Executive Director of Equity Research, Chief AI Strategist at Haitong International, the discussions brought together leaders from B Capital Group, the International Finance Corporation (IFC), EDBI, ABC Impact, Boehringer Ingelheim Venture Fund, VMS Group and LYFE Capital. The panel emphasized the pressing need to address financing gaps, noting that governments across the APAC region are grappling with the dual challenge of aging populations and shifting disease burdens, all while navigating economic pressures. They explored various strategies to expand the fiscal space for health, including leveraging non-traditional funding mechanisms, public-private partnerships, and outcome-based financing models.

The day one program also featured a “Singapore Night” networking dinner, in partnership with SGX Group and Han Kun Law Offices, highlighting by keynote speeches from Dr Wei Yang Cheong, Vice Provost at Singapore Management University and Senior Adviser (Health Economics) at the Ministry of Health, Singapore, Jin Hoe Koh, Executive Director at SGX Group and Aaron GU Partner of Han Kun Law Offices.

Creating a Climate-Resilient Health Future for Asia

?

The second day of the summit, in partnership with CIIP, opened with remarks by Deepali Khanna, Vice President for Asia at the Rockefeller Foundation, highlighting the critical need for innovative solutions and partnerships to address the region’s pressing healthcare and climate challenges.

This was followed by a panel on “The Impact of Climate Change on Health”, calling for industry action, moderated by Hong Ma, Executive Vice President, Advocacy and Engagement at Edelman APAC Health, featuring leaders from Global Asia Insurance Partnership (GAIP), the Health and Global Policy Institute (HGPI), the Asia Infrastructure Investment Bank (AIIB), and the World Economic Forum. Panellists explored the wide-ranging health impacts of climate change and emphasized the need for industry-wide action to build robust, adaptable healthcare systems in the region.

Building on this theme, followed a panel on “Decarbonizing the Healthcare Sector in Asia”, moderated by Jean-Gaetan GUILLEMAUD, Vice President Corporate Affairs, Zuellig Pharma, and convening leaders from SingHealth, DBS Bank, Philips, Roche and Apollo Hospitals. Discussions focused on reducing the healthcare sector’s carbon footprint and implementing sustainable practices through innovative supply chain strategies and cross-sector collaboration. ?“As we pursue our decarbonisation journey, our efforts fall into two main categories: infrastructure and culture. While the infrastructure aspect is straightforward, the cultural shift requires more attention. It’s not that our colleagues don’t care—they do. But we need to make it easy for them to do the right thing: to recycle, to reuse, and to actively participate in the sustainability journey amidst their demanding clinical responsibilities,” shared Professor Wan Cheng Chow, Group Director of Academic Medicine at SingHealth HQ and Vice Dean of Office of Academic Medicine at Duke-NUS School of Medicine.

Panel Discussions: Decarbonizing the Healthcare Sector in Asia

Showcase presentations followed, highlighting innovative solutions at the intersection of climate change and health. Representatives from the Centre for Impact Investing and Practices (CIIP), DBS Bank, the Embassy of the Kingdom of the Netherlands, and Landcent Group shared successful projects that demonstrated the power of public-private partnerships in creating scalable, sustainable solutions.

The summit concluded with a forward-looking panel on climate-resilient health systems, moderated by Renzo R. Guinto, Associate Professor of Global and Planetary Health at the SingHealth Duke-NUS Global Health Institute. Panellists from Bayer Foundation, Yale School of Public Health, Singapore University of Social Sciences (SUSS), Microsoft, and Digital Health China Technologies discussed strategies for enhancing health infrastructure, securing investment, and driving regional cooperation to address growing climate challenges. This comprehensive exploration of climate and health underscored the importance of collaboration, innovation, and policy action in building a sustainable and resilient future for healthcare across APAC. The panel discussed practical tools and strategies to drive resilience, such as automating processes, addressing social norms, and implementing standardized checklists. Specific examples included national disease surveillance systems, data-sharing platforms, and the integration of carbon tracking into digital health solutions.

Summit moderators (from left to right): Associate Professor Jonas KARLSTR?M, Core Lead of Innovation in Global Health at SingHealth Duke-NUS Global Health Institute, and Dr Chang LIU, Founder & CEO of ASK Health Asia and Adjunct Associate Professor at the Chinese University of Hong Kong

In closing remarks, Dr Chang Liu, the founder and CEO of Ask Health Asia expressed gratitude to all participants – speakers and attendees and noted the importance of continued collaboration across the Asia-Pacific region. Dr Chang Liu reflected, “This summit underscores the vital role APAC countries play in global healthcare innovation. By harnessing our shared strengths and fostering cooperation, we are building a future where healthcare is accessible, equitable, and resilient to climate impacts.”

For more information and to stay updated on APACLIFE2024, please visit the official website.

?

About SingHealth Duke-NUS Global Health Institute

The SingHealth Duke-NUS Global Health Institute (SDGHI) aims to advance health and wellbeing in Asia and beyond. Working in collaboration with partners, the Institute seeks to strengthen health systems, improve health outcomes and increase health security. Launched in 2018, SDGHI harnesses the capacity of SingHealth, the largest group of health care institutions in Singapore, and the Duke-NUS Medical School, to advance interdisciplinary global health research and capacity development across the region.

www.duke-nus.edu.sg/sdghi

About ASK Health Asia

ASK Health Asia is an Asia based think tank, consultancy, and venture builder in healthcare. Headquartered in Singapore, ASK Health Asia has extensive experience and operations in Southeast Asia, Mainland China, and Macau, with close partnership in India, Japan, Korea, Australia, and Middle East. ASK Health is a premier catalyst for health systems transformation in Asia. Through in-depth research, consultancy, platform development, solution co-creation and resource connection, we work closely with development partner, governments, and industry leaders to jointly capture growth opportunities from new health policies and provide innovative solutions to the economies across Asia.

www.askhealthasia.com?/?news.4e531j.cn

The post 2024 APAC Health and Life Sciences Summit: Global Leaders Gather to Shape a Sustainable and Resilient Future of Healthcare appeared first on 艾社康（上海）健康咨詢有限公司.

2024年8月30日-31日，第七屆中國(guó)多層次醫(yī)療保障體系創(chuàng)新論壇在北京圓滿舉辦。此次論壇由中國(guó)醫(yī)藥教育協(xié)會(huì)、北京康盟慈善基金會(huì)、中關(guān)村卓益慢病防治科技創(chuàng)新研究院、中關(guān)村精準(zhǔn)醫(yī)學(xué)基金會(huì)聯(lián)合發(fā)起，艾社康承辦。

復(fù)旦大學(xué)管理學(xué)院、復(fù)旦大學(xué)中國(guó)保險(xiǎn)與社會(huì)安全研究中心為論壇提供學(xué)術(shù)指導(dǎo)，RDPAC提供合作支持。阿斯利康、輝瑞、再鼎醫(yī)藥、第一三共、諾華、安進(jìn)、艾伯維、默克、衛(wèi)材、禮來(lái)、宸汐健康、商涌科技等多家行業(yè)領(lǐng)軍企業(yè)齊聚一堂，共同圍繞政策趨勢(shì)、熱點(diǎn)話題進(jìn)行深入探討與交流。

論壇獲得E藥經(jīng)理人、醫(yī)學(xué)界、新浪財(cái)經(jīng)提供戰(zhàn)略合作支持，并攜手鳳凰網(wǎng)財(cái)經(jīng)、健康國(guó)策、慢病界、醫(yī)衛(wèi)界、微解藥、醫(yī)藥魔方、醫(yī)谷以及眾多業(yè)內(nèi)主流媒體進(jìn)行宣傳報(bào)道。

本次論壇匯聚了來(lái)自醫(yī)保、衛(wèi)健、金融管理等多個(gè)領(lǐng)域的的政府領(lǐng)導(dǎo)、資深專家學(xué)者，以及來(lái)自保險(xiǎn)公司、藥械企業(yè)的產(chǎn)業(yè)代表，共筑多元化、高層次的交流平臺(tái)。論壇議程與頂層政策設(shè)計(jì)緊密銜接，讓與會(huì)者充分分享各自在多層次保障領(lǐng)域的豐富實(shí)踐經(jīng)驗(yàn)與成功案例。我們期望通過(guò)此次論壇，能夠凝聚社會(huì)各界的力量，形成共識(shí)，為人民群眾提供更加全面、優(yōu)質(zhì)的健康保障服務(wù)，助力健康中國(guó)戰(zhàn)略的深入實(shí)施，共同推動(dòng)我國(guó)多層次醫(yī)療保障事業(yè)邁向新的發(fā)展階段。

The post 第七屆中國(guó)多層次醫(yī)療保障體系創(chuàng)新論壇圓滿落幕 appeared first on 艾社康（上海）健康咨詢有限公司.

1月23日，在洛克菲勒基金會(huì)（The Rockefeller Foundation）的支持下，艾社康在曼谷PMAC 2024大會(huì)期間成功舉辦“科技創(chuàng)新助力建設(shè)有氣候韌性的城市和衛(wèi)生系統(tǒng)”研討會(huì)。

活動(dòng)匯集了來(lái)自學(xué)術(shù)、公共衛(wèi)生和慈善事業(yè)最前沿的跨部門領(lǐng)袖，共同探討中國(guó)在氣候-健康領(lǐng)域的創(chuàng)新、對(duì)亞洲地區(qū)的影響以及未來(lái)可能的合作方向。

在本次研討會(huì)中，艾社康正式發(fā)布了《Leveraging Data-Driven Solutions in Confronting Climate-Sensitive Diseases: China Case Study》報(bào)告。

（掃描下方二維碼 即可下載報(bào)告全文）

The post 艾社康于PMAC 2024大會(huì)期間舉辦“科技創(chuàng)新助力建設(shè)有氣候韌性的城市和衛(wèi)生系統(tǒng)”研討會(huì) appeared first on 艾社康（上海）健康咨詢有限公司.

由諾華公司組織和資助的 “患者創(chuàng)新和解決方案國(guó)際聯(lián)盟”（APPIS）平臺(tái)成立于 2021 年，旨在將患者社區(qū)和醫(yī)療保健生態(tài)系統(tǒng)中的主要利益相關(guān)者聚集在一起，優(yōu)先采取行動(dòng)，解決該地區(qū)患者在就醫(yī)過(guò)程中遇到的障礙。

自 APPIS 成立以來(lái)，已有來(lái)自 60 多個(gè)國(guó)家的 2,000 多人（包括 400 個(gè)患者組織、政策制定者、支付方、醫(yī)生、學(xué)者和數(shù)字創(chuàng)新者）在 APPIS 平臺(tái)上匯聚一堂，就患者創(chuàng)新和解決方案交流想法并開展合作。

艾社康榮幸受諾華集團(tuán)邀請(qǐng)，成為“患者創(chuàng)新和解決方案國(guó)際聯(lián)盟”的理事會(huì)成員。歡迎關(guān)注今年的APPIS全球峰會(huì)以及在亞太區(qū)域的系列項(xiàng)目。一起齊聚，只為患者！

The post 艾社康受邀成為“患者創(chuàng)新和解決方案國(guó)際聯(lián)盟”（APPIS）的理事會(huì)成員 appeared first on 艾社康（上海）健康咨詢有限公司.